CR depth with vemurafenib [10] or dabrafenib in relapsed/refractory HCL is lower (no MRD-negativity) compared to the anti-CD22 immunotoxin moxetumomab pasudotox (35% MRD-negative CR rate) [15], although we cannot exclude that BRAF inhibitor activity could deepen with more prolonged dosing. Here, BRAF is linked to hairy cell leukemia.